An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Phase 2
Completed
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 326
- Registration Number
- NCT02472145
A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT02470481
A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-42756493 Current Clinical Formulation (G-018)Drug: JNJ-42756493 Prototype Formulation I (G-025)Drug: JNJ-42756493 Prototype Formulation II (G-025)
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02466815
Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT02464046
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Phase 2
Terminated
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02462473
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Phase 1
Terminated
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, FollicularPrecursor Cell Lymphoblastic Leukemia-Lymphoma
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 59
- Registration Number
- NCT02454270
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Phase 3
Terminated
- Conditions
- Axial Spondyloarthritis
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 315
- Registration Number
- NCT02438787
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
Phase 3
Terminated
- Conditions
- Axial Spondyloarthritis
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 347
- Registration Number
- NCT02437162
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT02432703
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Phase 3
Completed
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 139
- Registration Number
- NCT02422186
© Copyright 2025. All Rights Reserved by MedPath